Proliferative Tumor Doubling Times of Prostatic Carcinoma
Prostate cancer (PCa) has a variable biology ranging from latent cancer to extremely aggressive tumors. Proliferative activities of cancers may indicate their biological potential. A flow cytometric assay to calculate maximum proliferative doubling times (Tmax) of PCa in radical prostatectomy specim...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Prostate Cancer |
| Online Access: | http://dx.doi.org/10.1155/2011/301850 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850219892814381056 |
|---|---|
| author | Priya N. Werahera L. Michael Glode Francisco G. La Rosa M. Scott Lucia E. David Crawford Kenneth Easterday Holly T. Sullivan Rameshwar S. Sidhu Elizabeth Genova Tammy Hedlund |
| author_facet | Priya N. Werahera L. Michael Glode Francisco G. La Rosa M. Scott Lucia E. David Crawford Kenneth Easterday Holly T. Sullivan Rameshwar S. Sidhu Elizabeth Genova Tammy Hedlund |
| author_sort | Priya N. Werahera |
| collection | DOAJ |
| description | Prostate cancer (PCa) has a variable biology ranging from latent cancer to extremely aggressive tumors. Proliferative activities of cancers may indicate their biological potential. A flow cytometric assay to calculate maximum proliferative doubling times (Tmax) of PCa in radical prostatectomy specimens after preoperative in vivo bromodeoxyuridine (BrdU) infusion is presented. Only 4/17 specimens had tumors large enough for flow cytometric analysis. The
Tmax
of tumors was similar and ranged from 0.6 to 3.6 months. Tumors had calculated doubling times 2- to 25-fold faster than their matched normal tissue. Variations in labeling index and
Tmax
were observed within a tumor as well as between different Gleason grades. The observed PSA doubling times (PSA-DT) ranged from 18.4 to 32.0 months, considerably slower than the corresponding
Tmax
of tumors involved. While lack of data for apoptotic rates is a limitation, apparent biological differences between latent versus aggressive PCa may be attributable to variations in apoptotic rates of these tumors rather than their cell proliferative rates. |
| format | Article |
| id | doaj-art-769fe663bfa9453b9f46ffc22a74aef5 |
| institution | OA Journals |
| issn | 2090-3111 2090-312X |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Prostate Cancer |
| spelling | doaj-art-769fe663bfa9453b9f46ffc22a74aef52025-08-20T02:07:14ZengWileyProstate Cancer2090-31112090-312X2011-01-01201110.1155/2011/301850301850Proliferative Tumor Doubling Times of Prostatic CarcinomaPriya N. Werahera0L. Michael Glode1Francisco G. La Rosa2M. Scott Lucia3E. David Crawford4Kenneth Easterday5Holly T. Sullivan6Rameshwar S. Sidhu7Elizabeth Genova8Tammy Hedlund9Department of Pathology, University of Colorado Anschutz Medical Campus, P.O. Box 6511, Aurora, CO 80045, USAMedical Oncology, University of Colorado Anschutz Medical Campus, CO 80045, USADepartment of Pathology, University of Colorado Anschutz Medical Campus, P.O. Box 6511, Aurora, CO 80045, USADepartment of Pathology, University of Colorado Anschutz Medical Campus, P.O. Box 6511, Aurora, CO 80045, USARadiation Oncology, University of Colorado Anschutz Medical Campus, CO 80045, USAPharmacy Department, University of Colorado Anschutz Medical Campus, CO 80045, USADepartment of Pathology, University of Colorado Anschutz Medical Campus, P.O. Box 6511, Aurora, CO 80045, USADepartment of Pathology, University of Colorado Anschutz Medical Campus, P.O. Box 6511, Aurora, CO 80045, USADepartment of Pathology, University of Colorado Anschutz Medical Campus, P.O. Box 6511, Aurora, CO 80045, USADepartment of Pathology, University of Colorado Anschutz Medical Campus, P.O. Box 6511, Aurora, CO 80045, USAProstate cancer (PCa) has a variable biology ranging from latent cancer to extremely aggressive tumors. Proliferative activities of cancers may indicate their biological potential. A flow cytometric assay to calculate maximum proliferative doubling times (Tmax) of PCa in radical prostatectomy specimens after preoperative in vivo bromodeoxyuridine (BrdU) infusion is presented. Only 4/17 specimens had tumors large enough for flow cytometric analysis. The Tmax of tumors was similar and ranged from 0.6 to 3.6 months. Tumors had calculated doubling times 2- to 25-fold faster than their matched normal tissue. Variations in labeling index and Tmax were observed within a tumor as well as between different Gleason grades. The observed PSA doubling times (PSA-DT) ranged from 18.4 to 32.0 months, considerably slower than the corresponding Tmax of tumors involved. While lack of data for apoptotic rates is a limitation, apparent biological differences between latent versus aggressive PCa may be attributable to variations in apoptotic rates of these tumors rather than their cell proliferative rates.http://dx.doi.org/10.1155/2011/301850 |
| spellingShingle | Priya N. Werahera L. Michael Glode Francisco G. La Rosa M. Scott Lucia E. David Crawford Kenneth Easterday Holly T. Sullivan Rameshwar S. Sidhu Elizabeth Genova Tammy Hedlund Proliferative Tumor Doubling Times of Prostatic Carcinoma Prostate Cancer |
| title | Proliferative Tumor Doubling Times of Prostatic Carcinoma |
| title_full | Proliferative Tumor Doubling Times of Prostatic Carcinoma |
| title_fullStr | Proliferative Tumor Doubling Times of Prostatic Carcinoma |
| title_full_unstemmed | Proliferative Tumor Doubling Times of Prostatic Carcinoma |
| title_short | Proliferative Tumor Doubling Times of Prostatic Carcinoma |
| title_sort | proliferative tumor doubling times of prostatic carcinoma |
| url | http://dx.doi.org/10.1155/2011/301850 |
| work_keys_str_mv | AT priyanwerahera proliferativetumordoublingtimesofprostaticcarcinoma AT lmichaelglode proliferativetumordoublingtimesofprostaticcarcinoma AT franciscoglarosa proliferativetumordoublingtimesofprostaticcarcinoma AT mscottlucia proliferativetumordoublingtimesofprostaticcarcinoma AT edavidcrawford proliferativetumordoublingtimesofprostaticcarcinoma AT kennetheasterday proliferativetumordoublingtimesofprostaticcarcinoma AT hollytsullivan proliferativetumordoublingtimesofprostaticcarcinoma AT rameshwarssidhu proliferativetumordoublingtimesofprostaticcarcinoma AT elizabethgenova proliferativetumordoublingtimesofprostaticcarcinoma AT tammyhedlund proliferativetumordoublingtimesofprostaticcarcinoma |